The National Institutes of Health is looking for help from thousands of Americans to participate in a new clinical trial testing a variety of vaccines and antibodies intended to protect people from COVID-19. Since the coronavirus pandemic emerged, most hopes for a return to normalcy have been pinned to the development of a vaccine that could greatly reduce the risk of infection and therefore help stop the spread of the virus. Federal officials have set up an online registry to enroll people from different age groups, races and health backgrounds to test potential vaccines. “Phase 3 trials is where you find out if the vaccine is effective, and safe in large numbers,” South Shore Health’s Dr. Todd Ellerin said. “Having a safe and effective medical countermeasure to prevent COVID-19 would enable us to not only save lives but also help end the global pandemic,” Dr. Anthony Fauci said. “Centralizing our clinical research efforts into a single trials network will expand the resources and expertise needed to efficiently identify safe and effective vaccines and other prevention strategies against COVID-19.”More than 100 clinical trial sites across the United States and internationally will be launched. The network has developed an extensive community engagement framework to reach out to potential research volunteers and explain the specific details involved in participating in a vaccine or monoclonal antibody clinical study. People also can learn more about the different stages of vaccine research and the new network’s COVID-19 vaccine and monoclonal antibody studies by visiting the COVPN’s website. The COVPN website features a customized data collection platform to securely identify potential trial participants. Interested individuals can sign up for a rolling clinical trial participant registry on the website, which features security-enhanced protections. Clinical study staff will use the registry to contact and screen potential study volunteers.The request for American’s help to find a vaccine comes as a new survey designed by a group at Tufts University found that just 57% of Americans said they would get a COVID-19 vaccine if one were available today.The national survey designed and analyzed by Tufts University’s Research Group on Equity in Health, Wealth and Civic Engagement, about 42% of respondents said they either would not get vaccinated (18%) or were unsure if they would get vaccinated (24%). “It’s really concerning that only 57% of our respondents said they would get vaccinated. It’s evident that we need to begin working on a national vaccine strategy and education campaign right now — even before we have the vaccine in hand,” Jennifer Allen, a Tufts professor and co-leader of the study, said.Tufts said that the results revealed divides in vaccination acceptance among various demographic groups.
BOSTON —
The National Institutes of Health is looking for help from thousands of Americans to participate in a new clinical trial testing a variety of vaccines and antibodies intended to protect people from COVID-19.
Since the coronavirus pandemic emerged, most hopes for a return to normalcy have been pinned to the development of a vaccine that could greatly reduce the risk of infection and therefore help stop the spread of the virus.
Federal officials have set up an online registry to enroll people from different age groups, races and health backgrounds to test potential vaccines.
“Phase 3 trials is where you find out if the vaccine is effective, and safe in large numbers,” South Shore Health’s Dr. Todd Ellerin said.
“Having a safe and effective medical countermeasure to prevent COVID-19 would enable us to not only save lives but also help end the global pandemic,” Dr. Anthony Fauci said. “Centralizing our clinical research efforts into a single trials network will expand the resources and expertise needed to efficiently identify safe and effective vaccines and other prevention strategies against COVID-19.”
More than 100 clinical trial sites across the United States and internationally will be launched.
The network has developed an extensive community engagement framework to reach out to potential research volunteers and explain the specific details involved in participating in a vaccine or monoclonal antibody clinical study.
People also can learn more about the different stages of vaccine research and the new network’s COVID-19 vaccine and monoclonal antibody studies by visiting the COVPN’s website.
The COVPN website features a customized data collection platform to securely identify potential trial participants. Interested individuals can sign up for a rolling clinical trial participant registry on the website, which features security-enhanced protections.
Clinical study staff will use the registry to contact and screen potential study volunteers.
The request for American’s help to find a vaccine comes as a new survey designed by a group at Tufts University found that just 57% of Americans said they would get a COVID-19 vaccine if one were available today.
The national survey designed and analyzed by Tufts University’s Research Group on Equity in Health, Wealth and Civic Engagement, about 42% of respondents said they either would not get vaccinated (18%) or were unsure if they would get vaccinated (24%).
“It’s really concerning that only 57% of our respondents said they would get vaccinated. It’s evident that we need to begin working on a national vaccine strategy and education campaign right now — even before we have the vaccine in hand,” Jennifer Allen, a Tufts professor and co-leader of the study, said.
Tufts said that the results revealed divides in vaccination acceptance among various demographic groups.
